Kayne Anderson Rudnick Investment Management
RPRX icon

Kayne Anderson Rudnick Investment Management’s Royalty Pharma RPRX Stock Holding History

Kayne Anderson Rudnick Investment Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.78K Buy
103
+81
+368% +$4.22K ﹤0.01% 780
2026
Q1 		$1.05K Hold
22
– – ﹤0.01% 844
2025
Q4 		$850 Hold
22
– – ﹤0.01% 887
2025
Q3 		$777 Sell
22
-119
-84% -$4.31K ﹤0.01% 916
2025
Q2 		$5.08K Buy
+141
New +$4.67K ﹤0.01% 764
2022
Q2 		– Sell
-54
Closed -$2K – 671
2022
Q1 		$2K Buy
+54
New +$2.12K ﹤0.01% 604

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management's RPRX Position: Q2 2026 in Review

Kayne Anderson Rudnick Investment Management increased its Royalty Pharma (RPRX) stake by 368% in Q2 2026, buying an estimated $4.22K and bringing the position to 103 shares worth $5.78K. The position accounts for ﹤0.01% of the portfolio, ranked #780.

Kayne Anderson Rudnick Investment Management first reported a position in RPRX in Q1 2022 and has held it in 6 quarters since. 643 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Kayne Anderson Rudnick Investment Management held 103 shares of Royalty Pharma worth $5.78K as of Q2 2026.
  • Kayne Anderson Rudnick Investment Management bought 81 Royalty Pharma shares in Q2 2026, an estimated $4.22K.
  • Royalty Pharma made up ﹤0.01% of Kayne Anderson Rudnick Investment Management's portfolio in Q2 2026, its #780 holding.
  • Kayne Anderson Rudnick Investment Management first reported a position in Royalty Pharma in Q1 2022 and has held it in 6 quarters since.
  • 643 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Kayne Anderson Rudnick Investment Management's 13F filing for Q2 2026, filed 13 Aug 2026.